Article Text

Download PDFPDF
Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity
  1. Ricardo Villela1,
  2. Ricardo Correa2
  1. 1 Deparment of Medicine, National Autonomous University of Honduras, Tegucigalpa, Francisco Morazán, Honduras
  2. 2 Department of Medicine, The University of Arizona College of Medicine - Phoenix and Phoenix VAMC, Phoenix, Arizona, USA
  1. Correspondence to Dr Ricardo Correa, Department of Medicine, The University of Arizona College of Medicine Phoenix and Phoenix VAMC, Phoenix, AZ 85022, USA; riccorrea20{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Overweight and obesity are one of the most relevant health factors; according to the WHO, 39% of people globally are overweight and 13% obese.1 Body weight loss of 3%–5% has been linked to a reduction in risk factors, whereas those with obesity and chronic illness should lose 5%–15% of their body weight to reduce risks.2 Glucose lowering medications, particularly glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs), might result in considerable weight loss.3 Semaglutide 2.4 mg (brand name Wegovy) was recently authorized by the Food and Drug Administration for chronic weight management. It is indicated in patients with a body mass index (BMI)≥30 kg/m2, or a BMI≥27 kg/m2 with comorbidities.4

The STEPs studies were the …

View Full Text

Footnotes

  • Twitter @drricardocorrea

  • Contributors All authors have substantially participated in the preparation and agree to be accountable for all aspects of work related to this Editorial. RV contributed to the conception, literature search, writing, editing, revision, and final approval of the manuscript. RRC contributed to the conception, literature search, writing, editing, revision, and final approval of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles